Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

REPL - Replimune Group, Inc. So'nggi Yangiliklar | Finranks

Home

REPL

R

Replimune Group, Inc. (REPL)

NMS – Real vaqt narxi. Valyuta: USD

7.22

-0.32 (-4.24%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

7.22

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 6:44 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect?

Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect?

The mean of analysts' price targets for Replimune Group (REPL) points to a 79.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Replimune to Present at Two Upcoming Investor Conferences

Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: Leerink Partners 2026 Global Healthcare ConferenceDate: Monday, March 9, 2026Fireside Chat Time: 2:20 pm EDT Jefferies 2026 Biotech on the Beach SummitDate: Tuesday, March 10, 20261x1 Meetings Live webcasts of the fireside chat will be available in the Investors section of Replimune's website at www.replimune.com.

Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know

Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know

The consensus price target hints at a 65.7% upside potential for Replimune Group (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2025 and provided a business update.

Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months

Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months

REPL shares soar 131.1% over the past three months after the FDA accepts its resubmitted BLA for the RP1/Opdivo combo in advanced melanoma.

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025 at 1:30 PM PT.

Videolar

No Data

There is no data to display

Press-relizlar

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2025 and provided a business update.

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2025 and provided a business update.

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026